12 international centres, 1028 pts: -preop RT dose boost in rectal cancer increase pCR rate particularly in T3-4 operated over week 11. -preop RT dose boost minimally but significantly increase acute toxicity. Radiotherapy & Oncology ESTRO Luca Nicosia MD 👇 sciencedirect.com/science/articl…

Anesthetic Considerations for Gynecologic HDR Brachytherapy sciencedirect.com/science/articl… Nice review on options. Don't think this is taught well during training but often learned on the job, which isn't ideal for the patient or the physician Lots depends on resources available...

📢🚨 Hot off the press The Lancet Oncology for #kidneycancer! shorturl.at/kAGVd. SABR vs thermal ablation; - Despite ⏫age, ⏬worse GFR, and ⏫tumours for SABR - SABR ⬆️effective than TA (at 1, 2 and 5 yrs) - esp for RCC >4cm - same renal decline (p=0.75) - similar F/U #radonc

The 1st Cyprus Oncological Congress is behind us! A really successful meeting, much needed by the local community, which sets the bar really high! Congrats to the organising committee #OEK #cyprusoncology

Why is the European uro-oncology community failing to provide guidelines for medically inoperable or technically inoperable T1b RCC (>4cm <=7cm)? Neither EUA or ESMO ESMO - Eur. Oncology provide guidance. #SABR should be an option at with level III evidence. LRMs are more important that SRMs!

2years of ADT after radical prostatectomy for high Risk #prostate #cancer patients did not improve MFS in phase III RCT AFU-GETUG 20 trial. #GU25 Need to identify better biomarkers of relapse Association Française d'Urologie - AFU GETUG Pr. Alexandre de La Taille Morgan Roupret Ploussard Guillaume

‼️ GROUQ-PCS 9 CRPC: ADT + enza vs ADT + Enza + SBRT to the conventionally (CT/MRI/bone scan) identified oligometastatic sites Primary endpt: rPFS = 4.6 years in the SBRT group and 2.3 years in the ADT and Enza arm, HR 0.5 (0.28-0.88) meetings.asco.org/abstracts-pres…

Metastasis-directed therapy improves outcomes in oligometastatic #ProstateCancer in #WOLVERINE study. Chad Tang, MD MD Anderson Cancer Center sits down with Leslie Ballas Cedars-Sinai to discuss a meta-analysis of STOMP, ORIOLE, ARTO, EXTEND & COMET-SABR trials on oligometastatic

Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials ascopubs.org/doi/abs/10.120… This study validates a novel

Cancer Bike Path stage 1 Vražne Johann Mendel House Cycling to #ESTRO2025 ESTRO #ThisIsBrachytherapy #Radiotherapy

Synthetic clinical data might solve privacy concerns and enhance data exchange in the future. Until now, we don’t know how to evaluate these datasets. Our new paper might solve this problem sciencedirect.com/science/articl… 1/4

Neil Desai Dr. Andrew Loblaw These are the studies I'm aware of with long f/u for HDR mono 2 fx. If 2 fx SBRT "working" then wonder if it's margins? Looks like maybe about 10% local failure with HDR which is higher than 4 or more fx regimens.

Radoncs need to be more represented when cancer is the topic and radiation therapy is object of discussion for patients. The multidisciplinary approach works when every cancer specialist can be a part of the decision. And radiation therapy is significant in most of guidelines.

new leadership team of GEC-ESTRO Urology (#UroGEC): 🔹Dr. Alfonso Gomez-Iturriaga, Alfonso Gomez-Iturriaga – Chair 🔹 Dr. Iosif Strouthos Iosif Strouthos – Secretary 🔹 Dr. med. Dr. Hathal Haddad Hathal Haddad – Social Media Ambassador ESTRO, ASTRO UroGec

GEC-ESTRO Urology – New Chair Announcement UroGec Alfonso Gomez-Iturriaga Iosif Strouthos oncodaily.com/blog/gec-estro… #Cancer #GEC_ESTRO #UroGEC #Brachytherapy #ESTRO25 #Medicine #Health #MedX #MedNews #MedEd #InterventionalRadiotherapy #Oncology #OncoDaily

#WhereisPeterHoskin? Spotted at the UroGec meeting during #ESTRO25 — always where the brachytherapy discussions happen! Alfonso Gomez-Iturriaga Iosif Strouthos Hathal Haddad Polska Brachyterapia Wielkopolskie Centrum Onkologii ESTRO

Our institution's narrative review on the antibiotic/antimicrobial use in brachytherapy for prostate, breast and gyn cancers. Heterogeneous usage - gap in knowledge - necessity for well-thought studies! German Oncology Center UroGec American Brachy academic.oup.com/jac/advance-ar…

KEYNOTE-641 & KEYNOTE-991 in Prostate Cancer What happens when you combine immunotherapy (pembrolizumab) with androgen receptor inhibitors (enzalutamide) in mCRPC & mHSPC? Let’s break down 2 major negative trials that teach us important lessons.👇 ⸻ 🔬 KEYNOTE-641: 📍

X-torial: Cleaning up the misinformation about Joe Biden and #ProstateCancer that I am reading everywhere. The purpose of this is to provide education from someone who treats and studies PCa for a living, lead the USA National Comprehensive Cancer Network (NCCN) PCa guidelines, hold leadership in NRG Oncology National Cancer Institute

Brachytherapy is an excellent treatment for prostate cancer which is organ preserving and highly effective. If you have been diagnosed with prostate cancer make sure you have all your options discussed including #brachytherapy for your own personal best outcome. #prostatecancer